PUBLIC COMPANY
save$CELCCelcuity Inc.
$CELC77.38-2.84%Minneapolis, MN, USupdated 16h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1pre_registration
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase2Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
- phase3Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
- phase3Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- —Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
Insider activity
source: SEC Form 4routine RSU / option mechanics (1)
- Apr 9, 26giftNIGON RICHARD · 10,000 sh
🐶 Hiring Signal
News
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 4mo ago
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that